+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cell & Gene Therapy Market - Global Outlook and Forecast 2020-2025

  • ID: 5135120
  • Report
  • August 2020
  • Region: Global
  • 266 pages
  • Arizton
UP TO OFF
until Sep 30th 2020
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Amgen
  • Biosolution
  • Corestem
  • JCR Pharmaceuticals
  • Nipro
  • Orthocell
  • MORE
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Cell and Gene Therapy Market Report

The global cell and gene therapy market by revenue is expected to grow at a CAGR of over 30.90% during the period 2019-2025.

The global cell and gene therapy market is one of the fastest-growing segments in the regenerative medicine market. The market is expected to grow at a faster pace during the forecast period. The demand can be attributed to the growing prevalence of several chronic diseases such as cancer, cartilage related problems, wounds, diabetic foot ulcer, genetic disorders, and other rare diseases across the globe. The prevalence of cancer and diabetes is increasing in the global population, which is influencing the growth of the market. There is a large unmet need in the treatment available, which is filled by cell and gene therapies. The market is growing due to the increased availability of funding from various public and private institutions. Besides, there is increased support from regulatory bodies for product approval. Several governments are creating awareness of cell and gene therapies in the population.

The following factors are likely to contribute to the growth of the cell and gene therapy market during the forecast period:
  • Increase in Strategic Acquisition Activities
  • Increased Funding for Cell & Gene Therapy Products
  • Expanding Applications of Cell and Gene Therapies
  • Increased in the Patient Pool
The study considers the present scenario of the cell and gene therapy market and its market dynamics for the period 2019−2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

Cell And Gene Therapy Market Segmentation

The global cell and gene therapy market research report includes a detailed segmentation by product, disease, end-user, and geography. In 2019, the cell therapy segment accounted for a market share of over 53% in the global cell and gene therapy market. The segment is expected to grow at a steady rate during the forecast period due to the increase in the target population and the rise in the number of countries preferring cell therapies in their patients. Increased therapeutic benefits are attracting several countries to invest in this technology and conduct a high number of clinical trials. However, the lack of advanced infrastructure in developing countries is hindering the growth of the segment.

In 2019, the oncology segment accounted for a share of over 40% in the global cell and gene therapy market. Oncology has been one of the targets of intense research for the gene therapy procedures & approach. More than 60% of on-going gene therapy clinical trials are targeting cancer. The segment is expected to grow at a promising rate on account of the high prevalence of cancer diseases, especially in low and middle-come countries. The market is growing at a double-digit CAGR, which is expected to help the segment as many cell and gene therapy for cancer are commercially available.

The dermatology application segment in the cell and gene therapy includes wound care management among patients. Vendors are focusing on the development and commercialization of advanced wound care products for the treatment of chronic and acute wounds, thereby increasing the growth of the wound care market. The increased pervasiveness of diabetics is increasing acute and chronic wounds, including surgical wounds, pressure ulcers, diabetic foot ulcers, and other wounds.

In 2019, the oncology segment accounted for a share of over 40% in the global cell and gene therapy market. Oncology has been one of the targets of intense research for the gene therapy procedures & approach. More than 60% of on-going gene therapy clinical trials are targeting cancer. The segment is expected to grow at a promising rate on account of the high prevalence of cancer diseases, especially in low and middle-come countries. The market is growing at a double-digit CAGR, which is expected to help the segment as many cell and gene therapy for cancer are commercially available.

The dermatology application segment in the cell and gene therapy includes wound care management among patients. Vendors are focusing on the development and commercialization of advanced wound care products for the treatment of chronic and acute wounds, thereby increasing the growth of the wound care market. The increased pervasiveness of diabetics is increasing acute and chronic wounds, including surgical wounds, pressure ulcers, diabetic foot ulcers, and other wounds.

Segmentation by Product
  • Cell Therapy
  • Gene Therapy
Segmentation by Disease
  • Dermatology
  • Musculoskeletal
  • Oncology
  • Genetic Disorders
  • Others
Segmentation by End-user
  • Hospitality
  • Cancer Care Centers
  • Wound Care Centers
  • Ambulatory Surgical Centers
  • Others
INSIGHTS BY GEOGRAPHY
In 2019, North America accounted for a share of over 60% of the global cell and gene therapy market. There are more than 530 regenerative medicine companies, including cell and gene therapy manufacturing developers. The number of products approved in North America grew significantly in 2019, with developers filed for marketing authorization for 10+ regenerative medicines, many of which we expect to be approved in 2020. Within the next 1-2 years, the number of approved gene therapies is expected to double. The US and Canada are the major contributors to the cell and gene therapy market in North America. Regulatory bodies are supporting several investigational products, fast track approvals, RMAT designation for the faster approval of the product into the market. The alliance for regenerative medicine and Medicare and Medicaid is working together to bring the structured reimbursement channels for cell and gene therapies.

Segmentation by Geography
  • North America
  • US
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • APAC
  • China
  • Japan
  • South Korea
  • Australia
  • India
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • Turkey
  • South Africa
  • UAE
INSIGHTS BY VENDORS
The global cell and gene therapy market is highly dynamic and characterized by the presence of several global, regional, and local vendors offering a wide range of therapies. Dendreon, Gilead Sciences, Novartis, Organogenesis, Osiris Therapeutics, Vericel, Amgen, and Spark Therapeutics are the leading players in the market with significant shares. Vendors such as NuVasive, APAC Biotech, Nipro, Orthocell, bluebird bio, J-TEC, and Terumo are the other prominent players in the market with a presence, especially in the cell therapy market. Most leading players are focusing on implementing strategies such as product launches and approvals, marketing and promotional activities, acquisitions, increased R&D investments, and strengthening their distribution networks to enhance their share and presence in the market.

Prominent Vendors
  • Gilead Sciences
  • Spark Therapeutics
  • Novartis
  • Organogenesis
  • Amgen
  • Osiris Therapeutics
  • Dendreon
  • Vericel
Other Prominent Vendors
  • Anterogen
  • Tego Sciences
  • Japan Tissue Engineering
  • JCR Pharmaceuticals
  • Medipost
  • MolMed
  • AVITA Medical
  • CollPlant
  • Biosolution
  • Stempeutics Research
  • Kolon Tissue Gene
  • Orchard Therapeutics
  • Sibiono GeneTech
  • NuVasive
  • Corestem
  • Pharmicell
  • Shanghai Sunway Biotech
  • RMS Regenerative Medical System
  • Takeda Pharmaceutical Company
  • CHIESI Farmaceutici
  • CO.DON
  • AnGes
  • GC Pharma
  • Human Stem Cells Institute
  • JW CreaGene
  • APAC Biotech
  • Nipro
  • Terumo
  • Orthocell
  • bluebird bio
KEY QUESTIONS ANSWERED
1. What is the cell and gene therapy market size and growth rate during the forecast period?
2. What are the factors impacting the growth of the cell and gene therapy market share?
3. How is the growth of the healthcare segment affecting the growth of the cell and gene therapy market?
4. Who are the leading vendors in the cell and gene therapy market, and what are their market shares?
5. Which product type/ end-user type/region is generating the largest revenue in the Asia Pacific region?
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen
  • Biosolution
  • Corestem
  • JCR Pharmaceuticals
  • Nipro
  • Orthocell
  • MORE
1 Research Methodology

2 Research Objectives

3 Research Process

4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of The Study
4.3.1 Market Segmentation by Product
4.3.2 Market Segmentation by Application
4.3.3 Market Segmentation by End-Users
4.3.4 Market Segmentation by Geography

5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation

6 Market at a Glance

7 Introduction
7.1 Overview
7.2 Cell and Gene Therapy: An Overview

8 Market Opportunities & Trends
8.1 Increase in Strategic Acquisitions
8.2 Robust Cell & Gene Therapy Pipeline
8.3 Increased Funding for Cell & Gene Therapy Products
8.4 Expanding Applications for Cell & Gene Therapies

9 Market Growth Enablers
9.1 Increasing Pool of Target Patients
9.2 Product Launches & Approvals
9.3 Regulatory Support & Special Designation for Cell & Gene Therapy Products
9.4 Growing Demand for Car T-Cell Therapies

10 Market Restraints
10.1 High Cost of Cell and Gene Therapy
10.2 Limitations of Gene Therapy Products
10.3 Availability of Alternative Treatments & Withdrawal of Products
10.4 Manufacturing & Operational Challenges with Cell & Gene Therapy Products
10.5 Low Product Penetration in LMICS

11 Market Landscape
11.1 Market Overview
11.2 Market Size & Forecast
11.3 Five Forces Analysis
11.3.1 Threat of New Entrants
11.3.2 Bargaining Power of Suppliers
11.3.3 Bargaining Power of Buyers
11.3.4 Threat of Substitutes
11.3.5 Competitive Rivalry

12 By Product
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Cell Therapy
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.4 Gene Therapy
12.4.1 Market Overview
12.4.2 Market Size & Forecast

13 By Application
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Oncology
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.4 Dermatology
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.5 Musculoskeletal
13.5.1 Market Overview
13.5.2 Market Size & Forecast
13.6 Genetic Disorders
13.6.1 Market Overview
13.6.2 Market Size & Forecast
13.7 Others
13.7.1 Market Overview
13.7.2 Market Size & Forecast

14 By End-user
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Hospitals
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.4 Wound Care Centers
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.5 Cancer Care Centers
14.5.1 Market Overview
14.5.2 Market Size & Forecast
14.6 AMBULATORY SURGICAL CENTERS
14.6.1 Market Overview
14.6.2 Market Size & Forecast
14.7 OTHERS
14.7.1 Market Overview
14.7.2 Market Size & Forecast

15 By Geography
15.1 Market Snapshot & Growth Engine
15.2 Geographic Overview

16 North America
16.1 Market Overview
16.2 Market Size & Forecast
16.3 Key Countries
16.3.1 US: Market Size & Forecast
16.3.2 Canada: Market Size & Forecast

17 Europe
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Key Countries
17.3.1 Germany: Market Size & Forecast
17.3.2 France: Market Size & Forecast
17.3.3 UK: Market Size & Forecast
17.3.4 Spain: Market Size & Forecast
17.3.5 Italy: Market Size & Forecast

18 APAC
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Key Countries
18.3.1 Japan: Market Size & Forecast
18.3.2 China: Market Size & Forecast
18.3.3 South Korea: Market Size & Forecast
18.3.4 Australia: Market Size & Forecast
18.3.5 India: Market Size & Forecast

19 Latin America
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Key Countries
19.3.1 Brazil: Market Size & Forecast
19.3.2 Mexico: Market Size & Forecast

20 Middle East & Africa
20.1 Market Overview
20.2 Market Size & Forecast
20.3 Key Countries
20.3.1 Turkey: Market Size & Forecast
20.3.2 Saudi Arabia: Market Size & Forecast
20.3.3 UAE: Market Size & Forecast
20.3.4 South Africa: Market Size & Forecast

21 Competitive Landscape
21.1 Competition Overview
21.2 Market Share Analysis
21.2.1 Gilead Sciences
21.2.2 Spark Therapeutics
21.2.3 Novartis
21.2.4 Amgen
21.2.5 Osiris Therapeutics
21.2.6 Denderon
21.2.7 Organogenesis
21.2.8 Vericel

22 Key Company Profiles
22.1 Gilead Sciences
22.1.1 Business Overview
22.1.2 Product Offerings
22.1.3 Key Strategies
22.1.4 Key Strengths
22.1.5 Key Opportunities
22.2 Spark Therapeutics
22.2.1 Business Overview
22.2.2 Product Offerings
22.2.3 Key Strategies
22.2.4 Key Strengths
22.2.5 Key Opportunities
22.3 Novartis
22.3.1 Business Overview
22.3.2 Product Offerings
22.3.3 Key Strategies
22.3.4 Key Strengths
22.3.5 Key Opportunities
22.4 Organogenesis
22.4.1 Business Overview
22.4.2 Product Offerings
22.4.3 Key Strategies
22.4.4 Key Strengths
22.4.5 Key Opportunities
22.5 AMGEN
22.5.1 Business Overview
22.5.2 Product Offerings
22.5.3 Key Strategies
22.5.4 Key Strengths
22.5.5 Key Opportunities
22.6 Osiris Therapeutics
22.6.1 Business Overview
22.6.2 Product Offerings
22.6.3 Key Strategies
22.6.4 Key Strengths
22.6.5 Key Opportunities
22.7 Dendreon
22.7.1 Business Overview
22.7.2 Product Offerings
22.7.3 Key Strategies
22.7.4 Key Strengths
22.7.5 Key Opportunities
22.8 Vericel
22.8.1 Business Overview
22.8.2 Product Offerings
22.8.3 Key Strategies
22.8.4 Key Strengths
22.8.5 Key Opportunities

23 Other Prominent Vendors
23.1 Anterogen
23.1.1 Business Overview
23.1.2 Product Offerings
23.2 Tego Sciences
23.2.1 Business Overview
23.2.2 Product Offerings
23.3 Japan Tissue Engineering (J-TEC)
23.3.1 Business Overview
23.3.2 Product Offerings
23.4 JCR Pharmaceuticals
23.4.1 Business Overview
23.4.2 Product Offerings
23.5 Medipost
23.5.1 Business Overview
23.5.2 Product Offerings
23.6 Molmed
23.6.1 Business Overview
23.6.2 Product Offerings
23.7 Avita Medical
23.7.1 Business Overview
23.7.2 Product Offerings
23.8 Collplant
23.8.1 Business Overview
23.8.2 Product Offerings
23.9 Biosolution
23.9.1 Business Overview
23.9.2 Product Offerings
23.10 Stempeutics Research
23.10.1 Business Overview
23.10.2 Product Offerings
23.11 Kolon Tissue Gene
23.11.1 Business Overview
23.11.2 Product Offerings
23.12 Orchard Therapeutics
23.12.1 Business Overview
23.12.2 Product Offerings
23.13 Sibiono Genetech
23.13.1 Business Overview
23.13.2 Product Offerings
23.14 Nuvasive
23.14.1 Business Overview
23.15 Corestem
23.15.1 Business Overview
23.16 Pharmicell
23.16.1 Business Overview
23.17 Shanghai Sunway Biotech
23.17.1 Business Overview
23.17.2 Product Offerings
23.18 RMS Regenerative Medical System
23.18.1 Business Overview
23.18.2 Product Offerings
23.19 Takeda Pharmaceutical Company
23.19.1 Business Overview
23.19.2 Product Offerings
23.20 Chiesi Farmaceutici
23.20.1 Business Overview
23.20.2 Product Offerings
23.21 CO.DON
23.21.1 Business Overview
23.21.2 Product Offerings
23.22 ANGES
23.22.1 Business Overview
23.22.2 Product Offerings
23.23 GC PHARMA
23.23.1 Business Overview
23.23.2 Product Offerings
23.24 Human Stem Cell Institute
23.24.1 Business Overview
23.25 JW CREAGENE
23.25.1 Business Overview
23.25.2 Product Offerings
23.26 APAC BIOTECH
23.26.1 Business Overview
23.26.2 Product Offerings
23.27 NIPRO
23.27.1 Business Overview
23.27.2 Product Offerings
23.28 TERUMO
23.28.1 Business Overview
23.28.2 Product Offerings
23.29 ORTHOCELL
23.29.1 Business Overview
23.29.2 Product Offerings
23.30 BLUEBIRD BIO
23.30.1 Business Overview
23.30.2 Product Offerings

24 Report Summary
24.1 Key Takeaways
24.2 Strategic Recommendations
25 Quantitative Summary
25.1 Market by Geography
25.2 Market by Therapy
25.3 Market by Aplications
25.4 Market by End-users

26 Appendix
26.1 Abbreviations
Note: Product cover images may vary from those shown
3 of 4
  • Gilead Sciences
  • Spark Therapeutics
  • Novartis
  • Organogenesis
  • Amgen
  • Osiris Therapeutics
  • Dendreon
  • Vericel
  • Anterogen
  • Tego Sciences
  • Japan Tissue Engineering
  • JCR Pharmaceuticals
  • Medipost
  • MolMed
  • AVITA Medical
  • CollPlant
  • Biosolution
  • Stempeutics Research
  • Kolon Tissue Gene
  • Orchard Therapeutics
  • Sibiono GeneTech
  • NuVasive
  • Corestem
  • Pharmicell
  • Shanghai Sunway Biotech
  • RMS Regenerative Medical System
  • Takeda Pharmaceutical Company
  • CHIESI Farmaceutici
  • CO.DON
  • AnGes
  • GC Pharma
  • Human Stem Cells Institute
  • JW CreaGene
  • APAC Biotech
  • Nipro
  • Terumo
  • Orthocell
  • bluebird bio
Note: Product cover images may vary from those shown
4 of 4

Our research comprises a mix of primary and secondary research. The secondary research sources that are typically referred to include, but are not limited to, company websites, annual reports, financial reports, company pipeline charts, broker reports, investor presentations and SEC filings, journals and conferences, internal proprietary databases, news articles, press releases, and webcasts specific to the companies operating in any given market.

Primary research involves email interactions with the industry participants across major geographies. The participants who typically take part in such a process include, but are not limited to, CEOs, VPs, business development managers, market intelligence managers, and national sales managers. We primarily rely on internal research work and internal databases that we have populated over the years. We cross-verify our secondary research findings with the primary respondents participating in the study.



 

Loading
LOADING...

Adroll
adroll